Therapeutic Drug Monitoring in Oncology: The key to individualised ...

Conclusions
• Expectation of TDM + other parameters
for reduced inter-patient variability and
reduced toxicity and improved efficacy.
• Little evidence that TDM actually
achieves this.
• Need large, prospective Phase III
studies using Bayesian approach